Webinar: From Mutation to Treatment: Understanding the Impact of IDH Inhibitors

Join this webinar to learn about the role of IDH inhibitors in brain tumor care and explore the latest advancements in IDH-targeted therapies, including the newly FDA-approved treatment, vorasidenib.

In this Webinar, you will:

• Understand what IDH inhibitors are and how they are diagnosed
• Learn about how IDH inhibitors influence treatment decisions
• Recognize the role of IDH inhibitors in treatment advancements and patient outcomes
• Q&A with presenter

Presenter: John de Groot, MD

Dr. John de Groot is a neuro-oncologist who specializes in diagnosing and managing the care of patients with primary brain and spine tumors.